General VAR Agreement
EyeGene has developed biopharmaceuticals such as diabetic retinopathy, pressure ulcer treatment, and cervical cancer vaccine. We also have experience in domestic and overseas commercialization of new bio drug technologies, so we have a lot of practical experience in pharmaceutical bio industry. The biggest advantage of EyeGene in carrying out the Bio informatics business is that we have excellent researchers and experts in QA and QC fields, so that we have a rich workforce to support the actual Dassault Systemes bio-system business. EyeGene has been in the biopharmaceutical business for 17 years, so we have close relationships with famous parmaceutical companies, national-private research institutes and general hospitals. In particular, we have a network of C-level executives of related parties.
We also invested in Aspens, a company that has long experience in license business as a product of Dassault Systemes.
In recent years, we have concluded an advisory contract with experts such as Professor Kim Chang-gyeom for bioinformatics business. Through these relationships, we have increased our IT business capabilities in addition to EyeGene's knowledge of bio pharmaceutical business.